Euroopan unioni - suomi - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - budesonidi / formoterol teva pharma b. on tarkoitettu aikuisille vain 18-vuotiaille ja vanhemmille. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiittiautia lukuun ottamatta kortikosteroideja - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - budesonide/formoterol teva on tarkoitettu aikuisille 18 vuotta täyttäneille vain. asthmabudesonide/formoterol teva on tarkoitettu säännölliseen astman hoitoon, jossa käytetään yhdistelmää (kortikosteroidi ja pitkävaikutteinen β2 adrenergisten reseptorien agonisti) on tarkoituksenmukaista:potilailla, joilla ei ole riittävästi hallinnassa hengitettävillä kortikosteroideilla ja "tarvittaessa" inhaloitava lyhytvaikutteinen β2 adrenoceptor agonistien. orin potilaat, jotka jo riittävästi hallintaan sekä inhaloitavia kortikosteroideja ja pitkävaikutteista β2 adrenoceptor agonistien. copdsymptomatic hoito potilailla, joilla on vaikea keuhkoahtaumatauti (fev1 < 50% viitearvosta normaali) ja ollut toistuvasti pahenemisvaiheita, jotka ovat merkittäviä oireita, vaikka säännöllinen hoito pitkävaikutteinen keuhkoputkia.

Euroopan unioni - suomi - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate vilanterolia trifenatate - astma - adrenergiset ja muut huumeet obstruktiivisille hengitysteiden sairauksille - astma indicationrevinty ellipta on tarkoitettu astman säännölliseen hoitoon aikuisilla ja vähintään 12-vuotiaille nuorille ja vanhemmille, jossa käytettävä yhdistelmävalmiste (pitkävaikutteinen beeta2-agonisti ja inhaloitava kortikosteroidi) on tarkoituksenmukaista:potilaat, jotka eivät ole riittävästi hallinnassa hengitettävillä kortikosteroideilla ja "tarvittaessa" inhaloitavaa lyhytvaikutteista beeta2-agonistit. copd indicationrevinty ellipta on tarkoitettu oireenmukaiseen hoitoon aikuisille, joilla on copd, joiden fev1.

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva b.v. - reslizumab - astma - muita systeemisiä obstruktiivisten hengitystiesairauksien lääkkeet, - cinqaero on ilmoitettu lisäosa hoitoa aikuisille joilla on vaikea eosinofiilinen astma, puutteellisesti valvotut huolimatta suurina annoksina hengitettynä kortikosteroidit plus toisen lääkkeen korvaushoitoon.

Euroopan unioni - suomi - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva b.v. - salmeteroliksinafoaatti, fluticasone propionate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.